
Reimbursement Still an Issue for Schering-Plough's Vytorin

Shares of Schering-Plough have fallen 20 percent since the drugmaker said Vytorin failed to meet its primary goal of helping to prevent fatty plaque build-up in carotid arteries than generic cholesterol fighter simvastatin.

Published on : Mon, 3 Mar 2008